JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 163 filers reported holding JUNO THERAPEUTICS INC in Q1 2016. The put-call ratio across all filers is 0.51 and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $645,000 | +11.0% | 14,121 | +9.0% | 0.00% | 0.0% |
| Q3 2017 | $581,000 | +54.9% | 12,955 | +3.1% | 0.00% | +100.0% |
| Q2 2017 | $375,000 | +36.9% | 12,562 | +1.7% | 0.00% | 0.0% |
| Q1 2017 | $274,000 | -57.3% | 12,352 | -63.6% | 0.00% | -66.7% |
| Q4 2016 | $641,000 | -46.4% | 33,980 | -14.7% | 0.00% | -40.0% |
| Q3 2016 | $1,196,000 | -23.8% | 39,850 | -2.4% | 0.01% | -16.7% |
| Q2 2016 | $1,570,000 | +403.2% | 40,850 | +398.8% | 0.01% | +500.0% |
| Q1 2016 | $312,000 | -16.8% | 8,190 | -3.9% | 0.00% | 0.0% |
| Q4 2015 | $375,000 | +3.6% | 8,520 | -4.2% | 0.00% | 0.0% |
| Q3 2015 | $362,000 | -25.8% | 8,890 | -2.8% | 0.00% | -50.0% |
| Q2 2015 | $488,000 | +2.5% | 9,150 | +16.7% | 0.00% | 0.0% |
| Q1 2015 | $476,000 | – | 7,840 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |